Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 2Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Radiation Injuries 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Papillomavirus Infections 1Lymphoma, Non-Hodgkin 1Lymphoma 1Hodgkin Disease 1

Interventions

Cyclophosphamide 125Peripheral Blood Stem Cell Transplantation 84fludarabine phosphate 81Etoposide 73Filgrastim 64Mycophenolic Acid 63Tacrolimus 57Whole-Body Irradiation 55Busulfan 52Doxorubicin 50Radiotherapy 48Melphalan 48Cyclosporine 47Brentuximab Vedotin 45Rituximab 39Vinblastine 37fludarabine 36Granulocyte Colony-Stimulating Factor 36Antilymphocyte Serum 35Prednisone 33Methotrexate 32Vincristine 31Gemcitabine 30Dacarbazine 29Bleomycin 29Cytarabine 26Carmustine 22Bendamustine Hydrochloride 21Sirolimus 18Ifosfamide 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Hodgkin Disease × Pentetic Acid × Clear all
NCT00001575 2015-12-07

Anti-Tac(90 Y-HAT) to Treat Hodgkin's Disease, Non-Hodgkin's Lymphoma and Lymphoid Leukemia

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
87 enrolled 11 charts
Lymphoid

Hodgkin Disease, Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡